David A. Siegel Arvinas, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arvinas, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 41,700 shares of ARVN stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,700
Previous 47,400
12.03%
Holding current value
$1.03 Million
Previous $1.96 Million
43.25%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ARVN
# of Institutions
224Shares Held
68.7MCall Options Held
166KPut Options Held
31.3K-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$166 Million6.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.67MShares$164 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$154 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.99MShares$98.2 Million0.01% of portfolio
-
Avidity Partners Management LP Dallas, TX2.99MShares$73.6 Million3.91% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.31B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...